Rhythm Pharmaceu Financials
Rhythm Pharmaceu (RYTM) reported $189.8M in revenue for fiscal year 2025, up 45.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
High gross margins are scaling revenue faster, but external funding still carries a business burning -$116.6M of free cash annually.
From FY2024 to FY2025, revenue scaled materially while gross margin held at89.7% , so the added sales did not come with weaker unit economics. Yet operating cash burn barely moved, from-$113.9M to-$115.7M , meaning the extra gross profit is still being absorbed by the cost base rather than becoming self-funding cash.
Asset-light reinvestment is unusually clear because free cash flow closely matched operating cash flow in each of the last three years, and capex was only
Balance-sheet repair was meaningful: debt-to-equity fell from 5.0x in FY2024 to 0.7x in FY2025, and equity recovered to
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Rhythm Pharmaceu's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Rhythm Pharmaceu scores 10.02, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($8.0B) relative to total liabilities ($341.1M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Rhythm Pharmaceu passes 4 of 9 financial strength tests. 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Rhythm Pharmaceu reported a net loss of $197K while operations used $115.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Rhythm Pharmaceu reported an operating loss of $192.0M against $20.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Rhythm Pharmaceu generated $189.8M in revenue in fiscal year 2025. This represents an increase of 45.8% from the prior year.
Rhythm Pharmaceu's EBITDA was -$191.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 27.7% from the prior year.
Rhythm Pharmaceu reported -$197K in net income in fiscal year 2025. This represents an increase of 24.6% from the prior year.
Rhythm Pharmaceu earned -$3.11 per diluted share (EPS) in fiscal year 2025. This represents an increase of 28.3% from the prior year.
Cash & Balance Sheet
Rhythm Pharmaceu recorded an outflow of $116.6M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 2.4% from the prior year.
Rhythm Pharmaceu held $54.3M in cash against $100.9M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Rhythm Pharmaceu's gross margin was 89.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. That is unchanged from the prior year.
Rhythm Pharmaceu's net profit margin was -0.1% in fiscal year 2025, showing the share of revenue converted to profit. This is up 0.1 percentage points from the prior year.
Rhythm Pharmaceu's ROE was -0.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 1.1 percentage points from the prior year.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Rhythm Pharmaceu invested $167.3M in research and development in fiscal year 2025. This represents a decrease of 29.7% from the prior year.
Rhythm Pharmaceu invested $953K in capex in fiscal year 2025, funding long-term assets and infrastructure.
Not reported for fiscal year 2025.
RYTM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $239.9M | $189.8M+45.8% | $130.1M+68.1% | $77.4M+227.6% | $23.6M+649.5% | $3.2M | $0 | $0 | $0 | $0 | $0 | N/A |
| Cost of Revenue | $26.4M | $19.5M+45.8% | $13.4M+43.7% | $9.3M+336.1% | $2.1M+256.1% | $599K | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $213.5M | $170.3M+45.8% | $116.8M+71.4% | $68.1M+216.8% | $21.5M+741.7% | $2.6M | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $173.2M | $167.3M-29.7% | $238.0M+76.3% | $135.0M+24.2% | $108.6M+4.3% | $104.1M+15.1% | $90.5M-17.4% | $109.5M+117.4% | $50.3M+119.9% | $22.9M+16.8% | $19.6M+174.1% | $7.1M |
| SG&A Expenses | $240.9M | $194.9M+35.1% | $144.3M+22.8% | $117.5M+27.7% | $92.0M+34.4% | $68.5M+48.5% | $46.1M+26.2% | $36.5M+30.2% | $28.1M+195.0% | $9.5M+50.8% | $6.3M+84.3% | $3.4M |
| Operating Income | -$200.6M | -$192.0M+27.7% | -$265.5M-44.0% | -$184.4M-2.9% | -$179.2M-5.3% | -$170.1M-24.5% | -$136.6M+6.5% | -$146.0M-86.2% | -$78.4M-141.9% | -$32.4M-25.1% | -$25.9M-145.0% | -$10.6M |
| Interest Expense | $18.5M | $20.6M-0.1% | $20.6M+48.3% | $13.9M+167.1% | $5.2M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $1.1M | $497K+43.6% | $346K-38.7% | $564K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$9.0M | -$197K+24.6% | -$261K-41.1% | -$185K-2.0% | -$181K-160.2% | -$70K+99.9% | -$134.0M+4.8% | -$140.7M-90.0% | -$74.1M-119.7% | -$33.7M-30.3% | -$25.9M-133.6% | -$11.1M |
| EPS (Diluted) | — | -$3.11+28.3% | -$4.34-35.6% | -$3.20+7.8% | -$3.47-147.9% | -$1.40 | -$3.04+21.2% | -$3.86 | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
RYTM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $480.2M+22.4% | $392.3M+17.9% | $332.7M-13.0% | $382.5M+16.1% | $329.5M+76.1% | $187.1M-39.4% | $308.5M+18.6% | $260.2M+71.5% | $151.7M+1129.7% | $12.3M | N/A |
| Current Assets | $466.9M+24.8% | $374.2M+21.4% | $308.3M-13.0% | $354.2M+14.9% | $308.4M+69.8% | $181.7M-39.9% | $302.4M+16.9% | $258.7M+71.7% | $150.7M+1248.3% | $11.2M | N/A |
| Cash & Equivalents | $54.3M-39.1% | $89.1M+48.4% | $60.1M-52.9% | $127.7M+115.5% | $59.2M-41.3% | $100.9M+61.9% | $62.3M+25.7% | $49.5M+44.7% | $34.2M+423.5% | $6.5M-81.2% | $34.9M |
| Inventory | $25.8M+37.4% | $18.7M+117.3% | $8.6M+195.6% | $2.9M+2527.9% | $111K | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $26.1M+40.9% | $18.5M+24.5% | $14.9M+138.9% | $6.2M+507.2% | $1.0M | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $341.1M-7.9% | $370.5M+127.3% | $163.0M+37.9% | $118.2M+160.6% | $45.4M+120.8% | $20.5M-25.3% | $27.5M+97.1% | $14.0M+100.8% | $6.9M-84.6% | $45.0M | N/A |
| Current Liabilities | $105.9M-8.3% | $115.5M+109.3% | $55.2M+38.7% | $39.8M-8.3% | $43.4M+141.3% | $18.0M-26.3% | $24.4M+79.8% | $13.6M+102.1% | $6.7M+42.0% | $4.7M | N/A |
| Long-Term Debt | $100.9M-6.8% | $108.3M+2.0% | $106.1M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $139.1M+540.0% | $21.7M-87.2% | $169.8M-35.8% | $264.3M-7.0% | $284.2M+70.6% | $166.5M-40.7% | $281.0M+14.1% | $246.3M+70.1% | $144.8M+542.7% | -$32.7M-308.8% | -$8.0M |
| Retained Earnings | -$1.4B-17.0% | -$1.2B-29.1% | -$894.7M-26.0% | -$710.1M-34.2% | -$528.9M-15.2% | -$459.3M-41.2% | -$325.3M-76.2% | -$184.6M-67.4% | -$110.3M-44.0% | -$76.5M | N/A |
Not reported in any period shown, so not listed: Goodwill.
RYTM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$105.3M | -$115.7M-1.6% | -$113.9M+16.4% | -$136.2M+21.5% | -$173.4M-18.8% | -$146.0M-19.7% | -$122.0M+0.6% | -$122.8M-97.8% | -$62.1M-110.6% | -$29.5M-26.9% | -$23.2M-243.9% | -$6.8M |
| Capital Expenditures | N/A | $953K | $0-100.0% | $47K-83.3% | $281K-35.3% | $434K+102.8% | $214K-93.7% | $3.4M+368.8% | $722K+442.9% | $133K-87.4% | $1.1M+6117.6% | $17K |
| Free Cash Flow | N/A | -$116.6M-2.4% | -$113.9M+16.4% | -$136.2M+21.6% | -$173.7M-18.6% | -$146.4M-19.8% | -$122.2M+3.1% | -$126.1M-100.9% | -$62.8M-112.1% | -$29.6M-21.9% | -$24.3M-258.6% | -$6.8M |
| Investing Cash Flow | -$144.9M | -$137.2M-184.7% | -$48.2M-750.4% | -$5.7M-120.2% | $28.0M+145.1% | -$62.2M-139.2% | $158.5M+666.8% | -$28.0M+67.9% | -$87.1M+20.8% | -$110.0M-2053.5% | -$5.1M-29958.8% | -$17K |
| Financing Cash Flow | $179.8M | $218.0M+14.0% | $191.2M+157.2% | $74.4M-65.2% | $213.8M+28.4% | $166.5M+8186.8% | $2.0M-98.8% | $163.5M-0.7% | $164.7M-1.5% | $167.2M | N/A | $41.7M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
RYTM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 89.7%0.0pp | 89.7%+1.7pp | 88.0%-3.0pp | 91.0%+10.0pp | 81.0% | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -101.2% | -204.0% | -238.1% | -757.9% | -5391.9% | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -0.1%+0.1pp | -0.2%0.0pp | -0.2%+0.5pp | -0.8%+1.4pp | -2.2% | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -0.1%+1.1pp | -1.2%-1.1pp | -0.1%0.0pp | -0.1%-0.1pp | 0.0%+80.4pp | -80.5%-30.4pp | -50.1%-20.0pp | -30.1%-6.8pp | -23.3% | N/A | N/A |
| Return on Assets | 0.0%0.0pp | -0.1%0.0pp | -0.1%0.0pp | -0.1%0.0pp | 0.0%+71.6pp | -71.6%-26.0pp | -45.6%-17.1pp | -28.5%-6.2pp | -22.2%+187.5pp | -209.7% | N/A |
| Current Ratio | 4.41+1.2x | 3.24-2.3x | 5.58-3.3x | 8.90+1.8x | 7.10-3.0x | 10.10-2.3x | 12.38-6.7x | 19.05-3.4x | 22.42+20.1x | 2.36 | N/A |
| Debt-to-Equity | 0.73-4.3x | 4.98+4.4x | 0.63+0.2x | 0.45+0.3x | 0.160.0x | 0.120.0x | 0.100.0x | 0.060.0x | 0.05 | N/A | N/A |
| FCF Margin | -61.5%+26.0pp | -87.5% | -175.9% | -734.9% | -4642.9% | N/A | N/A | N/A | N/A | N/A | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, FCF Margin.
Similar Companies
Where Rhythm Pharmaceu Ranks
Frequently Asked Questions
What is Rhythm Pharmaceu's annual revenue?
Rhythm Pharmaceu (RYTM) reported $189.8M in total revenue for fiscal year 2025. This represents a 45.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Rhythm Pharmaceu's revenue growing?
Rhythm Pharmaceu (RYTM) revenue grew by 45.8% year-over-year, from $130.1M to $189.8M in fiscal year 2025.
Is Rhythm Pharmaceu profitable?
No, Rhythm Pharmaceu (RYTM) reported a net income of -$197K in fiscal year 2025, with a net profit margin of -0.1%.
What is Rhythm Pharmaceu's EBITDA?
Rhythm Pharmaceu (RYTM) had EBITDA of -$191.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Rhythm Pharmaceu have?
As of fiscal year 2025, Rhythm Pharmaceu (RYTM) had $54.3M in cash and equivalents against $100.9M in long-term debt.
What is Rhythm Pharmaceu's gross margin?
Rhythm Pharmaceu (RYTM) had a gross margin of 89.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Rhythm Pharmaceu's net profit margin?
Rhythm Pharmaceu (RYTM) had a net profit margin of -0.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Rhythm Pharmaceu's return on equity (ROE)?
Rhythm Pharmaceu (RYTM) has a return on equity of -0.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Rhythm Pharmaceu's free cash flow?
Rhythm Pharmaceu (RYTM) recorded an outflow of $116.6M in free cash flow during fiscal year 2025. This represents a -2.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Rhythm Pharmaceu's operating cash flow?
Rhythm Pharmaceu (RYTM) recorded an outflow of $115.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Rhythm Pharmaceu's total assets?
Rhythm Pharmaceu (RYTM) had $480.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Rhythm Pharmaceu's capital expenditures?
Rhythm Pharmaceu (RYTM) invested $953K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Rhythm Pharmaceu spend on research and development?
Rhythm Pharmaceu (RYTM) invested $167.3M in research and development during fiscal year 2025.
What is Rhythm Pharmaceu's current ratio?
Rhythm Pharmaceu (RYTM) had a current ratio of 4.41 as of fiscal year 2025, which is generally considered healthy.
What is Rhythm Pharmaceu's debt-to-equity ratio?
Rhythm Pharmaceu (RYTM) had a debt-to-equity ratio of 0.73 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Rhythm Pharmaceu's return on assets (ROA)?
Rhythm Pharmaceu (RYTM) had a return on assets of 0.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Rhythm Pharmaceu's cash runway?
Based on fiscal year 2025 data, Rhythm Pharmaceu (RYTM) had $54.3M in cash against an annual operating cash burn of $115.7M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Rhythm Pharmaceu's Altman Z-Score?
Rhythm Pharmaceu (RYTM) has an Altman Z-Score of 10.02, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Rhythm Pharmaceu's Piotroski F-Score?
Rhythm Pharmaceu (RYTM) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Rhythm Pharmaceu's earnings high quality?
Rhythm Pharmaceu (RYTM) reported a net loss of $197K while operations used $115.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Rhythm Pharmaceu cover its interest payments?
Rhythm Pharmaceu (RYTM) reported an operating loss of $192.0M against $20.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Rhythm Pharmaceu?
Rhythm Pharmaceu (RYTM) scores 54 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.